NCT00479427已完成2 期
A Double-blind, Placebo Controlled Cross-over Study of the Effects of the CB2 Compound of GW842166 in Patients With Osteoarthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Change in pain scores from Baseline to the end of treatment Western Ontario and McMasters University Osteoarthritis Index (WOMAC) using on the pain subscore for 6-8 weeks
研究概览
简要总结
This is a double-blind, two-period, placebo controlled cross-over Phase IIa study. This study is to use CB2 compound of GW842166 in patients with osteoarthritis. The pain assessments and WOMAC questionnaires will be used in the study after the repeated dose to evaluate the efficacy of CB2 compound of GW842166.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, 50 to 80 years of age.
- •A female is eligible to participate in this study if she is of: a) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal (more than 1 year since last menstrual cycle), had a tubal ligation or is surgical sterilised); or, b) child-bearing potential, has a negative pregnancy test (urine) at screen and baseline, and agrees to one of the following:
- •Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; or
- •Implants of levonorgestral; or
- •Injectable progestogen; or
- •Oral contraception (combined or progestogen only); or
- •Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year; or
- •Barrier method only if used with any of the above acceptable methods.
- •A diagnosis of primary osteoarthritis of the knee at least 3 months in symptom duration prior to screen. For patients with OA in both knees, an index knee will be specified.
- •Meets American College of Rheumatology (ACR) criteria for symptomatic osteoarthritis of the knee as defined by knee pain and radiographic evidence of osteophytes (Altman 1986)
- •Global functional status I, II or III according to ACR classification (see Appendix 5).
- •Patient has a minimum of 40mm on the 100mm VAS (WOMAC pain subscale) at baseline / randomisation. In addition, baseline pain must be stable for at least 72 hours prior to randomisation based on patient's assessment.
- •Patient has a maximum of 80mm on the 100mm VAS (WOMAC pain subscale) at screening.
排除标准
- •Intolerance of paracetamol.
- •Any clinical or biological abnormality found at screening (other than those related to the disease under investigation) which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study (e.g. current malignancy, human immunodeficiency virus (HIV) infection, significant mental illness).
- •QTc ≥450msecs based on a 12-lead ECG obtained over a brief recording period. This applies to QTc intervals measured either by Bazzett's or Fridericia's formula (machine or manual over-read, male or female subjects).
- •Subjects with any one of creatinine, bilirubin, alanine aminotransferase (ALT) or aspartate aminotransfarase (AST) > 1.5 times the upper limit of normal (ULN) at screen are excluded. Subjects with two or more of bilirubin, ALT or AST above the ULN are excluded.
- •Chronic Hepatitis B and C, as evidenced by positive Hepatitis B surface antigen (HbsAg) or Hepatitis C antibody
- •History of chronic alcoholic liver disease
- •Impaired renal function (estimated GFR<30mL/min)
- •Use of potent CYP3A4 inhibitors (e.g. amiodarone, cyclosporine, diltiazem, elfinavir, indinavir, ritonavir, cimetidine, clarithromycin, erythromycin, fluconazole, itraconazole, ketoconazole, miconazole, nefazodone, verapamil)
- •Use of methotrexate.
- •Use of anticoagulants (warfarin, heparin) or anti-platelet aggregation agents (excluding low-dose aspirin) or a condition associated with decreased haemostasis
- •Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). 1 unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
- •A history of clinically significant drug or alcohol abuse, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria [Hochberg, 1991]
- •Participation in another investigational drug or device study during the 3 months prior to the Baseline/Randomisation Visit
- •Inability or unwillingness to comply with study restrictions
- •An unwillingness of male subjects to use a condom/spermicide, in addition to having their female partner use another form of contraception, such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation, if engaging in sexual intercourse with a female partner who could become pregnant. This criterion must be followed from the time of the first dose of study medication until three months after the last dose of study medication.
- •Exclusion criteria related to OA:
- •Secondary causes of arthritis of the knee including septic arthritis, inflammatory joint disease, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, and primary osteochondromatosis
- •Had lower extremity surgery (including arthroscopy) within 6 months prior to screening or scheduled for surgery of any kind during the study period
- •Significant prior injury to the index knee within 12 months prior to screen
- •Use of lower extremity assistive devices other than a cane or knee brace (use of a 'shoe lift' is permitted)
- •Disease of the spine or other lower extremity joints of sufficient degree to affect the index knee
- •Any other musculoskeletal or arthritic condition that may affect the interpretation of clinical efficacy and/or safety data or otherwise contraindicates participation in this clinical study (i.e., currently symptomatic fractures or any concurrent rheumatic disease such as but not limited to fibromyalgia, rheumatoid arthritis, and Reiter's syndrome are excluded)
- •Use of any analgesic, COX-2 inhibitor or NSAID [including topical NSAIDs; excluding low-dose aspirin (≤325mg per day)], other than protocol defined rescue therapy (paracetamol), within 5× half-life (in hours) prior to the first dosing day or during the study
- •Corticosteroid use prior to baseline as follows:
- •Intra-articular injection of steroids to the index knee within the previous 3 months
- •Intra-articular steroid injections into any site other than the index knee within the
- •Intra-muscular corticosteroid injections within the previous 3 months
- •Oral corticosteroids within the previous 1 month
- •Received hyaluronan injections into index knee within the previous six months prior to baseline
- •Initiation of or change to an established physiotherapy program within 2 weeks prior to baseline or during the study period. An established physiotherapy program may be continued throughout the study period if unchanged in frequency and intensity Recent start or change in dose regimen (≤3 months prior to baseline) of any OA-specific therapies (i.e., nutraceutical products) including but not limited to chondroitin or keratin sulfate, s-adenosyl methionine (SAMe) and glucosamine preparations
研究组 & 干预措施
Overall study
Experimental
overall study population
干预措施: GW842166 (Drug)
Overall study
Experimental
overall study population
干预措施: Placebo (Drug)
结局指标
主要结局
Change in pain scores from Baseline to the end of treatment Western Ontario and McMasters University Osteoarthritis Index (WOMAC) using on the pain subscore for 6-8 weeks
时间窗: Baseline (Day 1 pre-dose) and up to Day 14 of each treatment period (approximately up to 8 weeks)
The index consisted of 24 questions (5 for pain, 2 for stiffness and 17 for physical and composite functions). The visual analog scale (VAS; 0-100 millimeter \[mm\]) was utilized in this study and participants were asked to rate joint pain they had in last 24 hours in the 5 pain items. Participants were asked to rate pain while performing following activities: walking on a flat surface, going up or down stairs; at night while in bed; sitting or lying and standing upright. Higher score (100) indicates extreme pain and lower score (0) indicates no pain. It was assessed on Day 1 pre-dose (Baseline), Day 1 (1 hour post-dose) and Day 14 (2-4 hours post-dose). Change from Baseline was planned to be calculated by subtracting Baseline value from post-Baseline value. Due to the early termination of this study, no formal statistical analysis was performed. Only summarized data is available.
次要结局
- Quantitative Sensory Testing (QST) rating heat pain threshold and tolerance for 6-8 weeks(Up to Day 14 of each treatment period (approximately up to 8 weeks))
- Change from Baseline to the end of treatment in WOMAC stiffness subscore(Up to Day 14 of each treatment period (approximately up to 8 weeks))
- Pain intensity (100mm VAS) for the 40 meter self-paced walk test and for 11 step stair climb test(Up to Day 14 of each treatment period (approximately up to 8 weeks))
- Percentage of participants discontinuing due to lack of efficacy(Up to Day 14 of each treatment period (approximately up to 8 weeks))
- Average total daily use of rescue medication(Up to Day 14 of each treatment period (approximately up to 8 weeks))
- Change from baseline to the end of treatment in WOMAC physical function subscore(Baseline (Day 1 pre-dose) and up to Day 14 of each treatment period (approximately up to 8 weeks))
- Change from baseline to the end of treatment in participants' and Physician's Global assessment of arthritis condition(Baseline (Day 1 pre-dose) and up to Day 14 of each treatment period (approximately up to 8 weeks))
- Time for the 40 meter self-paced walk test and 11 step stair climb test(Up to Day 14 of each treatment period (approximately up to 8 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant EpilepsyDrug Resistant EpilepsyNCT04714996ES Therapeutics Australia Pty Ltd24
已完成
2 期
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic AsthmaAsthmaNCT01501942AIM Therapeutics Inc.11
已完成
2 期
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IIHereditary AngioedemaNCT04208412KalVista Pharmaceuticals, Ltd.84
已完成
2 期
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's DiseaseMild Cognitive ImpairmentDementiaNCT05104463CuraSen Therapeutics, Inc.64
已完成
2 期
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1DHypoglycemiaNCT03841526Xeris Pharmaceuticals48